U.S. Dried Blood Spot Collection Cards Market To Reach $149.9 Million By 2030

U.S. Dried Blood Spot Collection Cards Market Growth & Trends

The U.S. dried blood spot collection cards market size is anticipated to reach USD 149.9 million by 2030, growing at a CAGR of 3.9% during the forecast period, according to a new report by Grand View Research, Inc. The rising application in newborn screening and expanding utilization of DBS cards in forensic toxicology are significant factors contributing to the market growth. According to the U.S. Department of Health & Human Services (HSS) and Health Resources & Services Administration (HRSA), each state of the U.S. possesses its legal list of requirements for screening newborns.

The growing adoption of dried blood spot collection cards in forensic toxicology and their increasing use in newborn screening is expanding the scope of these valuable diagnostic tools. These cards offer several advantages, such as ease of sample collection, storage stability, and cost-effectiveness. In forensic toxicology, DBS cards enable efficient detection of various substances, including drugs, alcohol, and toxins, in individuals. This information is crucial for determining the cause of death and identifying potential criminals.

In newborn screening, DBS cards facilitate early detection of genetic disorders and metabolic diseases, allowing for timely interventions and improved health outcomes for infants. As research progresses and analytical techniques continue to advance, the utilization of DBS cards in these fields is expected to expand further, benefiting forensic investigations and newborn healthcare, and contributing to the market.

 Request a free sample copy or view report summary: U.S. Dried Blood Spot Collection Cards Market Report

U.S. Dried Blood Spot Collection Cards Market Report Highlights

• Based on application, the newborn screening segment held the largest revenue share of 23.19% in 2023 and is expected to grow at a significant CAGR of 3.3% during the forecast period. The growth is attributed to the larger number of newborn screenings in the U.S.

• Based in card type, the Whatman 903 segment dominated the market with the largest revenue share of 32.33% in 2023 and is expected to grow at the fastest CAGR throughout the forecast period

• Based on end-use, the hospitals & clinics segment accounted for the largest revenue share in 2023. The segment is expected to exhibit a lucrative CAGR over the forecast period

U.S. Dried Blood Spot Collection Cards Market Segmentation

Grand View Research has segmented the U.S. dried blood spot collection cards market based on application, card type, end-use, and region:

U.S. Dried Blood Spot Collection Cards Application Outlook (Revenue, USD Million, 2018 - 2030)

• Newborn Screening (NBS)

• Infectious Diseases Testing

• Therapeutic Drug Monitoring

• Forensics

• CRO/Research

• Other Applications

U.S. Dried Blood Spot Collection Card Type Outlook (Revenue, USD Million, 2018 - 2030)

• Whatman 903

• Ahlstrom 226

• FTA

• Others

U.S. Dried Blood Spot Collection Cards End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Clinics

• Diagnostics Centers

• Others

U.S. Dried Blood Spot Collection Cards Country Outlook (Revenue, USD Million, 2018 - 2030)

• West

• Midwest

• Northeast

• Southwest

• Southeast

List of Key Players in the U.S. Dried Blood Spot Collection Cards Market

• Whatman plc (Cytiva)

• GE Healthcare

• MilliporeSigma

• QIAGEN LLC

• PerkinElmer

• Roche

• Shimadzu Corporation

• Ahlstrom-Munksjö

• Eastern Business Forms, Inc.

• CENTOGENE N.V.